HRTX Covered Call Strategy
HRTX (Heron Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy.
HRTX (Heron Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $67.9M, a beta of 1.57 versus the broader market, a 52-week range of 0.38-2.3, average daily share volume of 3.0M, a public-listing history dating back to 1987, approximately 122 full-time employees. These structural characteristics shape how HRTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.57 indicates HRTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on HRTX?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current HRTX snapshot
As of June 30, 2026, spot at $0.42, ATM IV 226.20%, IV rank 47.50%, expected move 64.85%. The covered call on HRTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this covered call structure on HRTX specifically: HRTX IV at 226.20% is mid-range versus its 1-year history, so the credit collected on a HRTX covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 64.85% (roughly $0.27 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HRTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on HRTX should anchor to the underlying notional of $0.42 per share and to the trader's directional view on HRTX stock.
HRTX covered call setup
The HRTX covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HRTX near $0.42, the first option leg uses a $0.44 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HRTX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HRTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $0.42 | long |
| Sell 1 | Call | $0.44 | N/A |
HRTX covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
HRTX covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on HRTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on HRTX
Covered calls on HRTX are an income strategy run on existing HRTX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
HRTX thesis for this covered call
The market-implied 1-standard-deviation range for HRTX extends from approximately $0.15 on the downside to $0.69 on the upside. A HRTX covered call collects premium on an existing long HRTX position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether HRTX will breach that level within the expiration window. Current HRTX IV rank near 47.50% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on HRTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, HRTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HRTX-specific events.
HRTX covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HRTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HRTX alongside the broader basket even when HRTX-specific fundamentals are unchanged. Short-premium structures like a covered call on HRTX carry tail risk when realized volatility exceeds the implied move; review historical HRTX earnings reactions and macro stress periods before sizing. Always rebuild the position from current HRTX chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on HRTX?
- A covered call on HRTX is the covered call strategy applied to HRTX (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With HRTX stock trading near $0.42, the strikes shown on this page are snapped to the nearest listed HRTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HRTX covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the HRTX covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 226.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HRTX covered call?
- The breakeven for the HRTX covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HRTX market-implied 1-standard-deviation expected move is approximately 64.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on HRTX?
- Covered calls on HRTX are an income strategy run on existing HRTX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current HRTX implied volatility affect this covered call?
- HRTX ATM IV is at 226.20% with IV rank near 47.50%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.